Capital for Cures evening: royalty financing

Royalty and revenue-based financing are quietly becoming one of the most dynamic sources of capital in biotech. As traditional venture funding tightens and investors look for more predictable returns, royalty deals are bridging science and finance in new ways. Join us for an evening of discussion and networking with investors, family offices, and innovators exploring how this model is reshaping the way breakthroughs are funded.

Agenda

​5–5:45PM | Welcome drinks & networking

Join us for an informal start with drinks and introductions among investors, family offices, and biotech innovators.

​An opportunity to meet others interested in royalty and revenue-based financing models.

​5:45–6:25PM | Royalty Financing: Aligning Capital and Science

Moderator: Sebastian Gensior – Founder, Capital for Cures

​Speakers:

​Tanya Hughes, Investor & External Relations Lead, Cancer Research Horizons (TBC)

​Karan Mathur, Principal, Sagard Healthcare (TBC)

​Richard G. Gervase, Jr., Member of the Corporate and Securities and Intellectual Property Sections, Mintz

​Our panel brings together diverse perspectives from investors and dealmakers to institutional innovators to discuss how royalty financing can fund breakthroughs while preserving long-term value.

​6:25–8PM | Networking reception

Continue conversations over drinks and small bites.

Meet peers with deep experience in royalty financing.